Our previous studies have demonstrated that sclerostin antibody (Scl-Ab) treatment improves phosphate homeostasis, and increases bone mass, strength and mineralization in the <i>Hyp</i> mouse model of XLH. The gene discussed is SOST; the disease is X-linked hypophosphatemia.